XpresCheck offers Rapid Covid Testing
Tests now available at JFK & Newark
XpresCheck began
rapid testing for COVID-19
at both JFK International
Airport and Newark Liberty
International Airport
tomorrow on October
7, 2020. Rapid Testing represents
an expansion of
XpresCheck’s COVID-19
testing options which already
include the Polymerase
Chain Reaction
(PCR) Test and Blood Antibody
Test. Rapid testing
will also be available at all
future XpresCheck locations
after opening.
Said Doug Satzman,
XpresSpa Group CEO. “We
are pleased to now offer Abbott’s
portable, rapid molecular
ID NOW COVID-19
test, which has emerged as
a critical tool in the fight
against COVID-19 by delivering
on-the-spot results in
a matter of minutes. Having
a rapid test inside the
airport immediately upon
travel could also eliminate
the need for a full 14-day
quarantine in states where
that applies.”
The Abbott ID NOW is
a rapid molecular pointof
care test that delivers
COVID-19 results within
13 minutes. About the size
of a small kitchen appliance,
8 AIRPORT VOICE, OCTOBER 2020
ID NOW’s rapid results
and compact design
help make testing for active
COVID-19 infections
more accessible in non-traditional
settings. Giving
people real-time results
about their COVID-19 status
means they can more
confidently go about their
daily lives.
XpresCheck is working
with major airlines to support
creation of potential
air bridges between U.S.
cities and international
destinations, including,
but not limited to, New
York to London.
XpreCheck is engaged
in discussions with multiple
emerging Health Passport
Apps which would
link COVID-19 test results
from its partnered labs directly
into these apps. Passengers
would then be able
to show their test results
through these apps to airlines
and destinations so
as to ensure a hassle-free
entry and avoid quarantines,
where applicable
The ID NOW COVID-19
test has not been FDA
cleared or approved. It has
been authorized by the
FDA under an emergency
use authorization for use
by authorized laboratories
and patient care settings.
The test has been authorized
only for the detection
of nucleic acid from SARSCoV
2, not for any other viruses
or pathogens, and is
only authorized for the duration
of the declaration
that circumstances exist
justifying the authorization
of emergency use of in
vitro diagnostic tests for
detection and/or diagnosis
of COVID-19. Doug Salzman talks Rapid Vaccine to JFK